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The autism spectrum disorders (ASD) are a heterogeneous set of neurodevelopmental
syndromes defined by impairments in verbal and non-verbal communication, restricted
social interaction, and the presence of stereotyped patterns of behavior. The prevalence
of ASD is rising, and the diagnostic criteria and clinical perspectives on the disorder
continue to evolve in parallel. Although the majority of individuals with ASD will not
have an identifiable genetic cause, almost 25% of cases have identifiable causative
DNA variants. The rapidly improving ability to identify genetic mutations because
of advances in next generation sequencing, coupled with previous epidemiological
studies demonstrating high heritability of ASD, have led to many recent attempts to
identify causative genetic mutations underlying the ASD phenotype. However, although
hundreds of mutations have been identified to date, they are either rare variants affecting
only a handful of ASD patients, or are common variants in the general population
conferring only a small risk for ASD. Furthermore, the genes implicated thus far are
heterogeneous in their structure and function, hampering attempts to understand shared
molecular mechanisms among all ASD patients; an understanding that is crucial for the
development of targeted diagnostics and therapies. However, new work is beginning to
suggest that the heterogeneous set of genes implicated in ASD may ultimately converge
on a few common pathways. In this review, we discuss the parallel evolution of our
diagnostic and genetic understanding of autism spectrum disorders, and highlight recent
attempts to infer common biology underlying this complicated syndrome.
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CLINICAL PHENOTYPE AND INCIDENCE
Autism was first described 70 years ago by the American child psychiatrist Kanner (1943). While
originally reported by Kanner as an isolated syndrome with the core components being “obsessive
insistence on the preservation of sameness” and “autistic aloneness,” autism was considered mainly
as a childhood form of schizophrenia for more than 30 years (Eisenberg and Kanner, 1956). Autism
was first formally recognized as its own clinical diagnostic entity in 1980, defined as encompassing
three essential features: impairment in communication, lack of interest in other people, and
“bizarre” behaviors (American Psychiatric Association, 1980). Since that time, the criteria required
to obtain a diagnosis of ASD, and its relation to other similar disorders such as Asperger’s and Rett
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syndrome, have changed multiple times—reflecting both the
clinical heterogeneity of the disorder and the poor understanding
of its underlying pathophysiology.
The most recent definition of ASD recognizes abnormalities
in two clinical domains: ‘social and communication defects’
and “fixed interests and repetitive behaviors” (American
Psychiatric Association, 2013). All of the following three
symptoms describing persistent deficits in social interaction
and communication must be present for a diagnosis of ASD
to be made: (i) problems reciprocating social or emotional
interaction, inability to initiate an interaction, and problems
with shared attention or sharing of emotions and interests with
others; (ii) problems maintaining relationships and problems
adjusting to different social expectations; and (iii) nonverbal
communication problems such as abnormal eye contact,
posture, facial expressions, tone of voice, and gestures, as
well as an inability to understand these. Additionally, these
interaction/communication deficits cannot be better accounted
for by general developmental delay. Two of the four following
symptoms related to restricted and repetitive behavior must
also be present: (i) stereotyped or repetitive speech, motor
movements, or use of objects; (ii) excessive adherence to routines,
ritualized patters of verbal or nonverbal behavior, or excessive
resistance to change; (iii) highly restricted interests that are
abnormal in intensity or focus; and (iv) hyper- or hypo-reactivity
to sensory input or unusual interest in sensory aspects of the
environment.
Furthermore, the severity of each symptom must be defined
based on the level of support required for that symptom, in an
attempt to more thoroughly capture the “spectrum” nature of
the disease. In all cases, symptoms must have been present in
early childhood (even if initially unrecognized) although they
may not become fully manifest until later in life when social
demands exceed capacities. The symptoms must impair everyday
functioning, and cannot be better described by another diagnosis.
Autism spectrum disorders are one of the most common
neurodevelopmental problems affecting children in the Western
world. The most recent estimates have shown that ASD
affects between 1 in 68 children (Centers for Disease Control
Prevention, 2012) and perhaps as many as 1 in 50, (Blumberg
et al., 2013) depending on the methodology employed. This
represents a staggering 1.17–2% of all children. Boys are at least
four times more likely to receive a diagnosis of ASD as compared
to girls, (Centers for Disease Control Prevention, 2012) and this
ratio increases significantly when only mildly affected children
are considered (Gillberg et al., 2006). Furthermore, prevalence
estimates have been increasing substantially in recent years—
from 1 in 150 children in the year 2000—although it is unclear to
what extent this represents a true biological increase or is a result
of expanding diagnostic criteria and better clinical recognition of
the disorder (Fombonne, 2009).
The costs associated with autism are similarly great.
Economically, direct and indirect medical costs are estimated to
be over $3.2 million dollars per person over his or her lifetime,
or more than $34 billion dollars per year for all people with ASD
(Moldin and Rubenstein, 2006). Perhaps more importantly, the
emotional toll placed on parents and caregivers of children with
autism is immense, unrelenting, and has a serious impact on
family relationships, (Rao and Beidel, 2009) marriages, (Benson
and Kersh, 2011), and a couples’ future reproductive decisions
(Selkirk et al., 2009).
Consequently, it is of upmost urgency to patients with
ASD, their caregivers, and society at large that the underlying
cause(s) of the disorder is/are understood. Doing so will enable
the development of better, more specific diagnostic tests that
can recognize ASD earlier in life, which has been shown
to be important to improve long-term outcomes, (Howlin
et al., 2009) can provide parents with an explanation for their
child’s symptoms, and may eventually enable the development
of targeted therapeutics. Moreover, by understanding the
mechanisms that lead to the neurobehavioral autistic phenotype,
the field of human neuroscience as a whole can be advanced, as
it will provide insights into the genetic and molecular basis of
higher cognitive functioning.
However, the underlying pathophysiology of autism spectrum
disorders have long been a mystery. Various hypothesis ranging
from psychosocial to environmental have been purported, yet
it was not until twin and sibling epidemiological studies were
undertaken in the 1980s that the strong heritability of ASD began
to be realized. Subsequently, a large amount of work has firmly
established a significant genetic component to ASD’s etiology.
GENETIC ETIOLOGY
Evidence for a strong heritable risk of ASD was initially described
in twin and sibling epidemiological studies of autism, (Folstein
and Rutter, 1977) and has since been firmly established through
multiple genetic approaches (Geschwind, 2011). It was first
recognized that the risk of having a second child with autism
was higher in families that already had one child with ASD
than was the risk of having a child with ASD in the general
population. Originally this recurrence risk was estimated to be 5%
(compared with ∼1% in the general population), although more
recent estimates suggest it may be as high as 20% (Ozonoff et al.,
2011). Following these initial observations, the first twin studies
in ASD demonstrated a concordance rate approaching 90% in
monozygotic twins and 10% in dizygotic twins (Ritvo et al.,
1989; Steffenburg et al., 1989; Bailey et al., 1995; Smalley et al.,
1998). Subsequently, larger studies have shown the dizygotic
concordance rate to be at least greater than 20% (Hallmayer et al.,
2011).
These observations, coupled with the identification of
causative genetic mutations in monogenic disorders with autism
as a component, such as Fragile X and Rett syndromes, (Pieretti
et al., 1991; Amir et al., 1999) led to an ongoing effort to
identify genetic causes of “idiopathic” ASD using a number of
genomic approaches. As the technology behind these approaches
has improved, the ability to identify mutations with incredible
sensitivity and genomic resolution has resulted in over 700
genetic loci implicated in ASD to date (Freitag, 2007; Basu
et al., 2009; Anney et al., 2010). However, as more genes
and loci are identified, it is becoming increasingly clear that
the genomic architecture of ASD is incredibly heterogeneous
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and complex, necessitating a functional integration in order to
decipher common molecular mechanisms underlying ASD.
GENOMIC ARCHITECTURE OF ASD
The identification of genomic loci and individual genes
disrupted in patients with ASD has progressed in tandem with
the rapid development of sensitive genomic tools. Initially,
microscopically-visible chromosomal aberrations were observed
in patients with ASD who received karyotyping analysis. These
case reports were variable, but a number of loci were repeatedly
implicated, (Vorstman et al., 2006) including 7q11, 15q11–13,
and 22q11.2—regions already associated with syndromes that
had autistic symptoms as a component, and known to contain
a number of critical neurodevelopmental genes and some of the
first identified functional non-coding RNAs (Szafranski et al.,
2010; Mabb et al., 2011).
Subsequently, the development of microarray technology
such as comparative genomic hybridization (CGH), allowed the
unbiased assessment of copy-number variation (CNV) across
the whole genome at a resolution of as low as 100 kilobases
(Alkan et al., 2011). The first of these analysis indicated that
individuals with ASD had 10–20 times the number of CNVs as
controls (Jacquemont et al., 2006; Sebat et al., 2007). Numerous
studies have since used CGH or similar approaches to follow
up and improve upon these initial reports with larger and more
homogenous patient populations, with thousands of individuals
with ASD having been analyzed to date.(Autism Genome Project
Consortium et al., 2007; Christian et al., 2008; Marshall et al.,
2008; Glessner et al., 2009; Itsara et al., 2010; Pinto et al., 2010;
Cooper et al., 2011; Gilman et al., 2011; Sanders et al., 2011) These
studies have consistently demonstrated that individuals with ASD
havemore CNVs than non-related controls. Furthermore, studies
employing a family cohort model have been able to compare
individuals with ASD to their parents and unaffected siblings,
which has revealed that de novo CNVs in particular are more
frequent in children with ASD.
Functionally, it was also shown that larger CNVs (i.e., affecting
more genes) are associated with decreased cognition, (Girirajan
et al., 2012) and that females with ASD tend to have larger CNVs
than males with ASD, (Itsara et al., 2010; Sanders et al., 2011)
suggesting they are somehow more “genetically tolerant” of these
disruptions. Moreover, some of the identified loci result in nearly
opposite phenotypes depending on whether they are duplicated
or deleted (Jacquemont et al., 2011). Taken together, these
functional CNV findings suggest that identification of the genes
in these regions is not sufficient to understand the mechanisms
underlying autism, as it appears that a finely-regulated dosage
of each gene is necessary to avoid neurodevelopmental disorders
such as ASD.
Despite the progressmade withmicroarrays, the findings from
these studies only identified CNVs in 5–15% of individuals with
ASD, suggesting that other types of mutations must be operant
in ASD as well. However, investigations at higher genomic
resolution were traditionally limited to specific candidate genes
until the recent widespread availability of next-generation
sequencing (NGS) technologies and high resolution genome-
wide single nucleotide polymorphism (SNP) microarrays. Since
then, many large exome sequencing studies have been completed
in ASD, encompassing more than 1000 affected individuals
(O’Roak et al., 2011, 2012a,b; Klei et al., 2012; Kong et al.,
2012; Neale et al., 2012; Sanders et al., 2012). In addition to
identifying a number of high-confidence ASD candidate genes
(likely representing 5–10% of ASD cases), these studies provided
two other more broad insights into the functional genomics of
ASD that are particularly noteworthy. First, with the exception
of a few identified genes, there was very little replication of ASD
candidates among the studies. This had led to the notion that
many variants causative for the ASD phenotype are likely to
be very rare or “private” mutations, which are unlikely to be
found in more than one individual at the current scale with
which these studies are conducted—suggesting the number of
rare mutations that can impart substantial risk for ASD is much
larger than originally suspected. Secondly, a meta-analysis of
these studies at the group level showed that the average rate of
mutations in individuals with ASD was not significantly different
than control—or even unaffected siblings—unless the analysis
was restricted to genes that are known to be expressed during
human brain development (Sanders et al., 2012). This highlights
the tissue- and human-specific nature of gene function, which
underscores the importance of understanding the function of
ASD candidate genes in the context of human brain development
specifically, which remains a major challenge to the field.
Similarly, genome-wide association studies (GWAS) using
high resolution SNP arrays, which in contrast are designed to
assess for more common variants likely to increase autism risk
less substantially (i.e., variants founds in greater than 1% of the
population), have also not revealed a small set of genes likely to be
commonly found in patients with ASD (Autism Genome Project
Consortium et al., 2007; Wang et al., 2009; Weiss et al., 2009).
While GWAS approaches have indeed shown the importance of
common variants to ASD risk, (Gaugler et al., 2014) it has become
increasingly clear that the potential number of genes likely able to
confer moderately-sized risk for ASD is large and varied. In fact,
statistical modeling based on published results of both rare and
common variation have predicted that up to 1000–1500 genes
may ultimately be found to be associated with ASD (Iossifov et al.,
2012; Sanders et al., 2012). Therefore, understanding how such a
large and varied number of genes can all be associated with one
common clinical phenotype will end up being themajor challenge
to the field, once all implicated genes are identified.
Lastly, there is a growing appreciation that the presence of
multiple mutations and/or inherited protective or risk alleles—
each at different loci within one individual—may interact with
each other to result in the emergent ASD phenotype, and that
this may help explain the complex and heterogeneous nature of
ASD genomics. For instance, a number of studies have described
individuals with ASD who have more than one deleterious
mutation, (Girirajan et al., 2010, 2012; Leblond et al., 2012)
and the presence of more than one mutation correlates with an
increased risk of developmental delay (Girirajan et al., 2012).
Other studies have suggested certain inherited variants may
be protective against other ASD-causing mutations, especially
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in females (Robinson et al., 2013). While the identification of
multiple mutations within individuals is becoming a relatively
straightforward task, the challenge of understanding how
combinations of susceptibility genes interact during human brain
development to cause disease (epistasis) has only begun to be
explored.
FROM ASD CANDIDATE GENES TO
CANDIDATE PATHWAYS
Finally, several pathway analyses have been performed using
either genetic or transcriptome data to gain insight into the
biological functions associated with ASD candidate genes. For
instance, O’Roak et al. analyzed protein-interaction networks
among genes implicated in ASD via whole-exome sequencing
studies, and identified that de novo mutations in ASD patients
are overrepresented among proteins involved in a chromatin
remodeling network (O’Roak et al., 2012b). Similarly, Gilman
et al. demonstrated that CNVs identified in autistic patients are
enriched for genes involved in a molecular network related to
synaptogenesis, axon guidance, and neuronal motility (Gilman
et al., 2011).
A number of more recent studies have attempted to
integrate autism candidate genes with known human brain
gene expression patterns. Ben-David and Shifman attempted
to assess for differences between rare and common ASD
candidate genes by studying their co-expression relationships
in adult human brain. They discovered these genes were
both related to modules involved with synaptogenesis and
neuronal plasticity, and that are expressed in areas associated
with learning, memory, and sensory perception (Ben-David
and Shifman, 2012). The same authors also recently analyzed
the neurodevelopmental expression of ASD candidate genes
that had been discovered in cohorts as de novo mutations,
and demonstrated that these genes appear to relate to
networks involved in transcription regulation and chromatin
remodeling processes (Ben-David and Shifman, 2013). Using
the same neurodevelopmental transcriptional profiling dataset,
two other studies recently attempted to infer convergent
molecular pathways and neural circuits among various sets
of ASD candidate genes. An assessment of the co-expression
relationships among brain gene expression seeded with “high
confidence” ASD candidate genes suggested they are most highly
co-expressed during the mid-fetal developmental period, and in
layer 5/6 cortical projection neurons (Willsey et al., 2013). A
similar study assessing a broader list of ASD candidates suggested
that the heterogeneous genes may ultimately converge upon
the molecular pathways of transcriptional regulation in early
development, and synaptogenesis in later childhood (Parikshak
et al., 2013). While such studies are mainly exploratory in
nature, the provide some of the first insight that a few common
mechanisms may ultimately relate the heterogeneous set of ASD
candidate genes to one another.
CONCLUSION
In summary, a diagnosis of autism spectrum disorder is common,
and has an incredibly profound impact on individuals with
ASD, their families, and society at large. Because the underlying
cause(s) of ASD are not understood, specific diagnostic tests
and therapeutic strategies are unavailable. The evolution of
ASD’s clinical definition is indicative of the heterogeneous and
complex nature of the disorder. While ASD has been shown to
have a significant genetic etiological component, recent attempts
to discover genes associated with ASD risk have implicated
hundreds (now approaching thousands) of heterogeneous loci.
Moreover, this estimate does not even consider the emerging
role of non-coding RNA variants (Barry, 2014). Consequently,
attempts to understand how this diverse set of genes relates to
the underlying molecular mechanisms and subsequent cellular
neuropathology of ASD remains poorly understood.
This body of evidence suggests that while identification
of candidate genes in ASD is a critical first step toward
understanding the genetic etiology of this disorder, a
comprehensive, disorder-specific understanding of the molecular
mechanisms cannot be realized until the functional genomics of
ASD candidate genes are properly understood in the context of
human brain development. Therefore, studies that attempt to
reconcile the heterogeneous and varied nature of ASD genomics
are necessary to move the field forward toward a common
understanding of the mechanisms underlying the development
of ASD.
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